Given cyclically for short term use only: 
For the treatment of atrophic vaginitis, or kraurosis vulvae associated with the menopause.
The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptlyas possible. 
Attempts to discontinue or taper medication should be made at 3 to 6 month intervals. 
The usual dosage range is one or two applicatorsful per day for one or two weeks, then gradually reduced to one half initial dosage for a similar period. A maintenance dosage of one applicatorful, one to three times a week, may be used after restoration of the vaginal mucosa has been achieved. 
Treated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding. 
